Compartir
Este es el nuevo punto de información pensado para personal médico y pacientes sobre coronavirus de Elsevier. Aquí encontrará información experta y de calidad para la comunidad científica y los profesionales de la salud sobre el nuevo coronavirus (también denominado COVID-19 y 2019-nCoV)
Todos los recursos son de libre acceso para personal sanitario y pacientes.
Seleccione una especialidad
A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MITAPIVAT IN PATIENTS WITH SICKLE CELL DISEASE
KH Kuo, A Oluyadi, H Shao, S Morris, AU Zaidi, EJV Beers, SL Thein
10.1016/j.htct.2022.09.021
Hematol Transfus Cell Ther. 2022;44 Supl 2:S12-3
Open access
PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY
RRBN Presenter, N Shah, A Alencar, J Gerson, M Patel, W Jurczak, K Patel, A Mato, C Cheah, M Wang
10.1016/j.htct.2022.09.214
Hematol Transfus Cell Ther. 2022;44 Supl 2:S127
Open access
PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY
RR Barreto, K Patel, C Coombs, N Shah, T Eyre, W Wierda, P Ghia, M Davids, W Jurczak, A Mato
10.1016/j.htct.2022.09.235
Hematol Transfus Cell Ther. 2022;44 Supl 2:S139-40
Open access
REMISSÃO ESPONTÂNEA DE LEUCEMIA MIELOIDE AGUDA APÓS INFECÇÃO GRAVE POR COVID-19 E CHOQUE SÉPTICO: RELATO DE CASO.
LL Perruso, Pa dilha, VA Silva, FM Marques, P Teixeira, A Justino, SB Almeida, KP Mellilo, LLM Perobelli, EX Souto
10.1016/j.htct.2022.09.236
Hematol Transfus Cell Ther. 2022;44 Supl 2:S140-1
Open access
INIBIDORES DE PROTEÍNAS DA FAMÍLIA BCL-2 CONTRA NEOPLASIAS HEMATOLÓGICAS E SEUS EFEITOS NA COMBINAÇÃO COM CITARABINA, VENETOCLAX E DOXORRUBICINA
MLP Bueno, LL Artico, ADS Santos, A Bastos, JA Yunes, STO Saad, FM Roversi
10.1016/j.htct.2022.09.243
Hematol Transfus Cell Ther. 2022;44 Supl 2:S144-5
Open access
POLICITEMIA VERA JAK2 V617F NÃO MUTADO, COM MUTAÇÃO DA CALRETICULINA TIPO 2: RELATO DE CASO
FG Porto, IGHL Metze, PM Campos, GB Oliveira, GBD Amarante, IBR Filgueiras, EPS Silva, CC Barbosa, AA Schenka, KBB Pagnano
10.1016/j.htct.2022.09.378
Hematol Transfus Cell Ther. 2022;44 Supl 2:S224
Open access
FOCAL ADHESION KINASE INHIBITION DECREASES CELL VIABILITY AND INDUCES APOPTOSIS IN SET-2 CELLS
ACMM Valente, MBM Pereira, RT Ribeiro
10.1016/j.htct.2022.09.379
Hematol Transfus Cell Ther. 2022;44 Supl 2:S224-5
Open access
QUADRO CLÍNICO FAVORÁVEL DE PACIENTES COM DOENÇA FALCIFORME E COVID-19: RELATOS DE CASO
MT Alves, CM Silva, MB Oliveira, FFC Carvalho, TS Borborema, MCM Vasconcelos, MCF Silva-Malta, AK Vieira
10.1016/j.htct.2022.09.103
Hematol Transfus Cell Ther. 2022;44 Supl 2:S62
Open access
O IMPACTO DA PANDEMIA DE COVID-19 NO ATENDIMENTO DO PACIENTE COM LEUCEMIA
AKO Moura, MAF Filho, RNC Silva, EBS Nogueira, MFND Rêgo
10.1016/j.htct.2022.09.1071
Hematol Transfus Cell Ther. 2022;44 Supl 2:S624
Open access
A RETOMADA DAS ATIVIDADES DE EXTENSÃO DE UMA LIGA DE HEMATOLOGIA NO CONTEXTO DA PANDEMIA DE COVID-19: RELATO DE EXPERIÊNCIA
FM Reis, NBA Miranda, FMN Souza, CDC Lima, JVS Valadares, LC Lins, GC Casas, WM Medeiros, VSA Silva, JMC Oliveira
10.1016/j.htct.2022.09.1079
Hematol Transfus Cell Ther. 2022;44 Supl 2:S628-9
Open access